We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Blood MicroRNA Biomarker Distinguishes Myocarditis from Myocardial Infarction

By LabMedica International staff writers
Posted on 08 Jun 2021
Print article
Image: First biomarker in blood that distinguishes myocarditis from an acute myocardial infarction (Photo courtesy of Centro Nacional De Investigaciones Cardiovasculares)
Image: First biomarker in blood that distinguishes myocarditis from an acute myocardial infarction (Photo courtesy of Centro Nacional De Investigaciones Cardiovasculares)
A novel microRNA has been found that can be used to distinguish patients with myocarditis from those with myocardial infarction.

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Myocarditis is usually diagnosed after coronary angiography or computed tomography scans have ruled out coronary artery disease, followed by confirmation of the diagnosis by magnetic resonance imaging (MRI). However, not all centers have access to MRI technology, and the current gold standard for myocarditis diagnosis is endomyocardial biopsy, an invasive procedure normally reserved for severe cases. Thus a pressing clinical need exists for the development of reliable and accessible tools for the early diagnosis of acute myocarditis.

In this regard, investigators at the Centro Nacional de Investigaciones Cardiovasculares (Madrid, Spain) and their collaborators in Spain and abroad sought to identify a novel microRNA for the diagnosis of acute myocarditis.

To identify a microRNA specific for myocarditis, they performed microRNA microarray analyses and quantitative polymerase-chain-reaction (qPCR) assays in sorted CD4+ T cells and type 17 helper T (Th17) cells after inducing experimental autoimmune myocarditis or myocardial infarction in mice. They then identified the human homologue for this microRNA and compared its expression in plasma obtained from patients with acute myocarditis with the expression in various controls.

Results revealed that the human homologue, designated hsa-miR-Chr8:96, could be identified in four independent cohorts of patients with myocarditis. The area under the receiver-operating-characteristic curve for this novel microRNA for distinguishing patients with acute myocarditis from those with myocardial infarction was 0.927. The microRNA retained its diagnostic value in models after adjustment for age, sex, ejection fraction, and serum troponin level.

"Our finding has great potential as a valuable clinical tool for the precise and noninvasive diagnosis of myocarditis from small drops of blood," said senior author Dr. Pilar Martín, a research professor at the Centro Nacional de Investigaciones Cardiovasculares.

The myocarditis paper was published in the May 27, 2021, online edition of The New England Journal of Medicine.

Related Links:
Centro Nacional de Investigaciones Cardiovasculares

Gold Supplier
Virus Transport and Preservation Medium – Inactivated
Virus Transport and Preservation Medium – Inactivated
New
Molecular Diagnostics System
ePlex System
New
Quantitative SARS-CoV-2 Neutralizing Antibody ELISA
KTR-1036 EDI Quantitative SARS-CoV-2 Neutralizing Antibody ELISA
New
Silver Supplier
AUTOSAMPLER - CHORUS ACCESSORY
AUTOSAMPLER - CHORUS ACCESSORY

Print article

Channels

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.